Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.3% - Here's What Happened

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) traded down 7.3% on Monday . The company traded as low as $18.78 and last traded at $18.88. 438,978 shares traded hands during trading, a decline of 50% from the average session volume of 871,433 shares. The stock had previously closed at $20.37.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. JMP Securities reaffirmed a "market outperform" rating and set a $89.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. Citigroup assumed coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. Finally, HC Wainwright dropped their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics currently has a consensus rating of "Buy" and an average target price of $76.17.

Structure Therapeutics Price Performance

The stock has a 50-day simple moving average of $23.05 and a 200 day simple moving average of $23.32. The company has a market capitalization of $1.07 billion, a PE ratio of -21.53 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Virtus ETF Advisers LLC lifted its position in shares of Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after acquiring an additional 455 shares in the last quarter. Geode Capital Management LLC lifted its position in Structure Therapeutics by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 45,705 shares of the company's stock worth $1,240,000 after buying an additional 480 shares during the period. ANTIPODES PARTNERS Ltd lifted its position in Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after buying an additional 553 shares during the period. LPL Financial LLC lifted its position in Structure Therapeutics by 6.0% during the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company's stock worth $311,000 after buying an additional 646 shares during the period. Finally, Envestnet Asset Management Inc. lifted its position in Structure Therapeutics by 12.9% during the fourth quarter. Envestnet Asset Management Inc. now owns 7,403 shares of the company's stock worth $201,000 after buying an additional 843 shares during the period. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.